Israel Englander Freeline Therapeutics Holdings PLC Transaction History

Millennium Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.42 - $0.63 $56,983 - $85,474	135,674 Added 511.21%	162,214 $75,000
Q4 2022 Feb 14, 2023	BUY	$0.46 - $0.73 $12,208 - $19,374	26,540 New	26,540 $13,000
Q3 2021 Nov 15, 2021	SELL	$3.04 - $8.9 $181,299 - $530,778	-59,638 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$8.15 - $13.9 $58,785 - $100,260	-7,213 Reduced 10.79%	59,638 $486,000
Q1 2021 May 17, 2021	SELL	$12.3 - $18.2 $64,021 - $94,731	-5,205 Reduced 7.22%	66,851 $822,000
Q4 2020 Feb 16, 2021	SELL	$14.94 - $18.3 $782,482 - $958,462	-52,375 Reduced 42.09%	72,056 $1.32 Million
Q3 2020 Nov 16, 2020	BUY	$15.45 - $18.12 $1.92 Million - $2.25 Million	124,431 New	124,431 $1.94 Million

30.1K

Ticker FRLN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,972,300
Description
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in P...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.